{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059740","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.374109+00:00","generated_at":"2026-06-08T14:54:52.776724+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Synlogic earns $2.5M milestone payment from Roche for IBD program","bullets":["Third milestone achieved under June 2021 Roche collaboration for Synthetic Biotic in IBD.","$2.5 million payment triggered; previous milestones in Sep 2021 and Aug 2022.","Roche retains exclusive option to license and commercialize the candidate.","Synlogic's Synthetic Biotics are oral, gut-restricted biotherapeutics for serious diseases.","Mylene Perreault, VP Research, emphasizes compelling fit with IBD disease biology."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059740","json":"https://secwatch.observer/filing/0000950170-23-059740.json","markdown":"https://secwatch.observer/filing/0000950170-23-059740.md","text":"https://secwatch.observer/filing/0000950170-23-059740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023059740/0000950170-23-059740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023059740/sybx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:54:52.776724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}